Galectin Therapeutics (GALT) Change in Accured Expenses (2010 - 2026)

Galectin Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 450.77% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $8.6 million, a 179.28% increase from a year earlier, with the FY2025 full-year figure at $6.2 million, up 40.43% from the prior year.
• Change in Accured Expenses slipped to $1.8 million in Q1 2026 per GALT's latest filing, from $9.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $9.8 million in Q4 2025 and bottomed at -$3.4 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is $843000.0 (2024), against an average of $1.1 million.
• Across the five-year window, Change in Accured Expenses surged 4778.05% in 2022 and slumped 1033.33% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.3 million in 2022, then jumped by 51.78% to $5.1 million in 2023, then grew by 18.04% to $6.0 million in 2024, then soared by 63.84% to $9.8 million in 2025, then tumbled by 81.35% to $1.8 million in 2026.
• Per Business Quant, the three latest GALT Change in Accured Expenses figures stand at $1.8 million (Q1 2026), $9.8 million (Q4 2025), and -$345000.0 (Q3 2025).